ArticleScientific reports2025
A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The safety of daptomycin in infants under 1 year old remains uncertain. This study aimed to identify signals potentially associated with daptomycin use in this special population based on the Food and Drug Administration adverse event reporting system (FAERS). Real-world pharmacovigilance research was conducted on the FAERS database from Q1 2004 to Q2 2024. Disproportionality analyses, including reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN), were used to assess the strength of AEs signals for daptomycin. A subgroup analysis was conducted on the data from the past 5 years to further explore the association between AEs and daptomycin. A total of 96 AEs of daptomycin as the primary suspected drug used in infants under 1 year old were reported, and 8 risk signals involving 3 system organ classes(SOCs) were identified as simultaneously meeting the 4 algorithms. The strongest associations were observed for hepatobiliary disorders (ROR 8.54), renal and urinary disorders (ROR 4.55), infections and infestations (ROR 3.68) in SOCs, and the top 4 signal intensities of AEs were hepatic cytolysis (ROR 297.93), drug reaction with eosinophilia and systemic symptoms (DRESS) (ROR 92.54), acute kidney injury (ROR 20.99), hypotension (ROR 14.10). In the subgroup analysis, 4 positive risk signals for AEs were identified, which were distributed across 3 SOCs. Among these, hepatobiliary disorders (ROR 10.98) topped the list. The strongest associations were observed for hepatic cytolysis (ROR 226.08), DRESS (ROR 110.04) in positive risk signals. The results highlight the new daptomycin AEs signals in younger infants and provide vital risk monitoring and identification support. In our analysis, hepatic cytolysis and DRESS were the most significant risk signals, and no positive signals related to the nervous system were observed. Additionally, due to the limitations of the FAERS, the correlation between AEs and daptomycin warrants cautious interpretation, and further explorations in the future are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.